Literature DB >> 25421459

Summary report of PQRI Workshop on Nanomaterial in Drug Products: current experience and management of potential risks.

Jeremy A Bartlett1, Marcus Brewster, Paul Brown, Donna Cabral-Lilly, Celia N Cruz, Raymond David, W Mark Eickhoff, Sabine Haubenreisser, Abigail Jacobs, Frank Malinoski, Elaine Morefield, Ritu Nalubola, Robert K Prud'homme, Nakissa Sadrieh, Christie M Sayes, Hripsime Shahbazian, Nanda Subbarao, Lawrence Tamarkin, Katherine Tyner, Rajendra Uppoor, Margaret Whittaker-Caulk, William Zamboni.   

Abstract

At the Product Quality Research Institute (PQRI) Workshop held last January 14-15, 2014, participants from academia, industry, and governmental agencies involved in the development and regulation of nanomedicines discussed the current state of characterization, formulation development, manufacturing, and nonclinical safety evaluation of nanomaterial-containing drug products for human use. The workshop discussions identified areas where additional understanding of material attributes, absorption, biodistribution, cellular and tissue uptake, and disposition of nanosized particles would continue to inform their safe use in drug products. Analytical techniques and methods used for in vitro characterization and stability testing of formulations containing nanomaterials were discussed, along with their advantages and limitations. Areas where additional regulatory guidance and material characterization standards would help in the development and approval of nanomedicines were explored. Representatives from the US Food and Drug Administration (USFDA), Health Canada, and European Medicines Agency (EMA) presented information about the diversity of nanomaterials in approved and newly developed drug products. USFDA, Health Canada, and EMA regulators discussed the applicability of current regulatory policies in presentations and open discussion. Information contained in several of the recent EMA reflection papers was discussed in detail, along with their scope and intent to enhance scientific understanding about disposition, efficacy, and safety of nanomaterials introduced in vivo and regulatory requirements for testing and market authorization. Opportunities for interaction with regulatory agencies during the lifecycle of nanomedicines were also addressed at the meeting. This is a summary of the workshop presentations and discussions, including considerations for future regulatory guidance on drug products containing nanomaterials.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25421459      PMCID: PMC4287304          DOI: 10.1208/s12248-014-9701-9

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  54 in total

1.  Polymerized micelles and their use as adjuvants in immunology.

Authors:  G Birrenbach; P P Speiser
Journal:  J Pharm Sci       Date:  1976-12       Impact factor: 3.534

Review 2.  Nanomedicine(s) under the microscope.

Authors:  Ruth Duncan; Rogerio Gaspar
Journal:  Mol Pharm       Date:  2011-10-26       Impact factor: 4.939

3.  Nanobiotechnology: nanoparticle coronas take shape.

Authors:  Marco P Monopoli; Francesca Baldelli Bombelli; Kenneth A Dawson
Journal:  Nat Nanotechnol       Date:  2011-01       Impact factor: 39.213

4.  Optimization of formulation and process variable of nanosuspension: An industrial perspective.

Authors:  Dhananjay S Singare; Seshasai Marella; K Gowthamrajan; Giriraj T Kulkarni; Rajesh Vooturi; Parchuri Srinivasa Rao
Journal:  Int J Pharm       Date:  2010-10-07       Impact factor: 5.875

5.  Common pitfalls in nanotechnology: lessons learned from NCI's Nanotechnology Characterization Laboratory.

Authors:  Rachael M Crist; Jennifer Hall Grossman; Anil K Patri; Stephan T Stern; Marina A Dobrovolskaia; Pavan P Adiseshaiah; Jeffrey D Clogston; Scott E McNeil
Journal:  Integr Biol (Camb)       Date:  2013-01       Impact factor: 2.192

Review 6.  Parameters influencing the stealthiness of colloidal drug delivery systems.

Authors:  Arnaud Vonarbourg; Catherine Passirani; Patrick Saulnier; Jean-Pierre Benoit
Journal:  Biomaterials       Date:  2006-05-02       Impact factor: 12.479

Review 7.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

Review 8.  Controlling drug nanoparticle formation by rapid precipitation.

Authors:  Suzanne M D'Addio; Robert K Prud'homme
Journal:  Adv Drug Deliv Rev       Date:  2011-04-30       Impact factor: 15.470

9.  Pharmacokinetics of liposome-encapsulated anti-tumor drugs. Studies with vinblastine, actinomycin D, cytosine arabinoside, and daunomycin.

Authors:  R L Juliano; D Stamp
Journal:  Biochem Pharmacol       Date:  1978-01-01       Impact factor: 5.858

10.  Forming biocompatible and nonaggregated nanocrystals in water using amphiphilic polymers.

Authors:  William W Yu; Emmanuel Chang; Joshua C Falkner; Junyan Zhang; Ali M Al-Somali; Christie M Sayes; Judah Johns; Rebekah Drezek; Vicki L Colvin
Journal:  J Am Chem Soc       Date:  2007-02-20       Impact factor: 15.419

View more
  9 in total

Review 1.  Nanomaterial Drug Products: Manufacturing and Analytical Perspectives.

Authors:  Christie M Sayes; Grace V Aquino; Anthony J Hickey
Journal:  AAPS J       Date:  2016-11-07       Impact factor: 4.009

Review 2.  How Has CDER Prepared for the Nano Revolution? A Review of Risk Assessment, Regulatory Research, and Guidance Activities.

Authors:  Katherine M Tyner; Nan Zheng; Stephanie Choi; Xiaoming Xu; Peng Zou; Wenlei Jiang; Changning Guo; Celia N Cruz
Journal:  AAPS J       Date:  2017-04-18       Impact factor: 4.009

Review 3.  The evolving landscape of drug products containing nanomaterials in the United States.

Authors:  Sheetal R D'Mello; Celia N Cruz; Mei-Ling Chen; Mamta Kapoor; Sau L Lee; Katherine M Tyner
Journal:  Nat Nanotechnol       Date:  2017-04-24       Impact factor: 39.213

Review 4.  Clinical Translation of the National Institutes of Health's Investments in Nanodrug Products and Devices.

Authors:  Lori A Henderson; Lalitha K Shankar
Journal:  AAPS J       Date:  2016-12-19       Impact factor: 4.009

5.  Nanomedicines in the EU-Regulatory Overview.

Authors:  Ruben Pita; Falk Ehmann; Marisa Papaluca
Journal:  AAPS J       Date:  2016-08-15       Impact factor: 4.009

Review 6.  Polymeric micelles for the delivery of poorly soluble drugs: From nanoformulation to clinical approval.

Authors:  Duhyeong Hwang; Jacob D Ramsey; Alexander V Kabanov
Journal:  Adv Drug Deliv Rev       Date:  2020-09-24       Impact factor: 15.470

Review 7.  The consolidation of nanomedicine.

Authors:  Raphael Zingg; Marius Fischer
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2019-06-26

Review 8.  The Hitchhiker's Guide to Human Therapeutic Nanoparticle Development.

Authors:  Thelvia I Ramos; Carlos A Villacis-Aguirre; Katherine V López-Aguilar; Leandro Santiago Padilla; Claudia Altamirano; Jorge R Toledo; Nelson Santiago Vispo
Journal:  Pharmaceutics       Date:  2022-01-21       Impact factor: 6.321

Review 9.  Nanomedicine for COVID-19: the role of nanotechnology in the treatment and diagnosis of COVID-19.

Authors:  Farzan Vahedifard; Krishnan Chakravarthy
Journal:  Emergent Mater       Date:  2021-02-13
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.